Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ADMA with free AI briefings, catalyst countdowns, and dilution alerts.

ADMA · ADMA Biologics Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$136M Cash on Hand

CF+ Cash Runway

Follow ADMA by email Get an email when ADMA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADMA, unsubscribe in one click. Privacy

📣 What ADMA Says Is Next

by year-end · “ADMA continues to advance plasma collection optimization, potency assay development and preclinical activities supporting planned conformance lot production during the second half of 2026, ahead of the anticipated submission of its pre-Investigational New Drug (IND) meeting package to the U.S. Food and Drug Administration by year-end.”
Company press release, Aug 5, 2026 · SEC filing
fourth quarter · “The Company expects to provide a reconciliation of Adjusted EBITDA and Adjusted Net Income to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 audited financial results.”
Company press release, Feb 25, 2026 · SEC filing
in 2026 · “ADMA advanced SG-001 preclinical development in 2025 and plans to submit a pre-Investigational New Drug (IND) meeting package to the FDA in 2026, potentially enabling direct progression into a registrational trial.”
Company press release, Feb 25, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Aug 2022 · Phase 4 · Results Expected · Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Sub
Registry primary completion date, not a results date
Dec 2014 · Phase 3 · Results Expected · Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Imm
Registry primary completion date, not a results date
May 2010 · Phase 2 · Results Expected · RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of
Registry primary completion date, not a results date
Jul 2009 · Phase 3 · Results Expected · Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Asceniv™	Primary Immune Deficiency	Phase 4 · NCT05070455	Unknown
Bivigam	Humoral Immune Response	Phase 4 · NCT03164967	Completed
Nabi-IGIV 10% [Immune Globulin Intraveno	Primary Immune Deficiency Disorders (PIDD)	Phase 3 · NCT00538915	Completed
Therapeutic Immune Globulin	Primary Immune Deficiency Disorder	Phase 3 · NCT01814800	Completed
Therapeutic Hepatitis C Immune Globulin	Sequelae of Viral Hepatitis	Phase 2 · NCT00473824	Terminated
High-titer RSV Immune Globulin RI-001	Upper Respiratory Tract Infection	Phase 2 · NCT00632463	Completed
Other	Primary Immune Deficiency Disorder	N/A · NCT03037359	Unknown

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADMA holds $136M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADMA files for a raise →

👥 Who Owns ADMA

Insiders 3% Institutions (439 holders) 92.8% Public and other holders 4.2%

Holder	Type	Shares	% of shares	As of
STATE STREET CORPORATION	Institution (13G, 5%+)	17,116,022	7.64%	2026-06-30
Vanguard Capital Management	Institution (13G, 5%+)	12,110,153	5.41%	2026-03-31
Adam S Grossman President and CEO, Director · +1.14M options	Insider	2,693,734	1.20%	2026-03-16
Steve Elms Director · +17,730 options	Insider	2,143,750	0.96%	2026-03-05
Jerrold B Grossman Director · +17,730 options	Insider	520,459	0.23%	2026-05-27
Kaitlin M. Kestenberg-Messina COO and SVP, Compliance · +155,801 options	Insider	443,061	0.20%	2026-07-24
Young Kwon Director · +17,730 options	Insider	263,020	0.12%	2026-02-09
Brad L. Tade CFO and Treasurer	Insider	232,940	0.10%	2026-02-19
Lawrence P. Guiheen Director · +41,567 options	Insider	156,510	0.07%	2026-03-13
Terry Kohler CFO and Treasurer · +136,363 options	Insider	143,149	0.06%	2026-07-16
Alison Cecily Finger Director · +17,730 options	Insider	45,619	0.02%	2026-02-09
Eduardo Rene Salas Director · +17,730 options	Insider	21,579	0.01%	2026-02-09

Share count 223,984,680 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z